Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCRIPT
2022-501710-62-02Phase 4Authorised
- Sponsor
- LYSARC
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), T-cell lymphoma follicular helper (TFHL) and 2 more (2 arms), sponsored by LYSARC. Primary endpoint: Modified progression-free survival. Planned start Apr 2023; status: authorised.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)T-cell lymphoma follicular helper (TFHL)follicular T-cell lymphoma (FTCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2022-501710-62-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501710-62-02.